- Home
- XENE vs FOLD Comparison
XENE vs FOLD Comparison
Compare XENE & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- FOLD
- Stock Information
- Founded
- XENE 1996
- FOLD 2002
- Country
- XENE Canada
- FOLD United States
- Employees
- XENE N/A
- FOLD N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- FOLD Health Care
- Exchange
- XENE Nasdaq
- FOLD Nasdaq
- Market Cap
- XENE 3.0B
- FOLD 3.5B
- IPO Year
- XENE 2014
- FOLD 2007
- Fundamental
- Price
- XENE $42.23
- FOLD $10.09
- Analyst Decision
- XENE Strong Buy
- FOLD Strong Buy
- Analyst Count
- XENE 10
- FOLD 8
- Target Price
- XENE $57.30
- FOLD $17.57
- AVG Volume (30 Days)
- XENE 367.1K
- FOLD 2.5M
- Earning Date
- XENE 11-12-2024
- FOLD 11-06-2024
- Dividend Yield
- XENE N/A
- FOLD N/A
- EPS Growth
- XENE N/A
- FOLD N/A
- EPS
- XENE N/A
- FOLD N/A
- Revenue
- XENE N/A
- FOLD $493,671,000.00
- Revenue This Year
- XENE N/A
- FOLD $33.97
- Revenue Next Year
- XENE $1,600.08
- FOLD $21.74
- P/E Ratio
- XENE N/A
- FOLD N/A
- Revenue Growth
- XENE N/A
- FOLD 32.58
- 52 Week Low
- XENE $28.10
- FOLD $9.02
- 52 Week High
- XENE $50.99
- FOLD $14.57
- Technical
- Relative Strength Index (RSI)
- XENE 48.00
- FOLD 33.34
- Support Level
- XENE $41.42
- FOLD $10.73
- Resistance Level
- XENE $44.61
- FOLD $11.36
- Average True Range (ATR)
- XENE 1.40
- FOLD 0.46
- MACD
- XENE -0.15
- FOLD -0.17
- Stochastic Oscillator
- XENE 25.94
- FOLD 1.16
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.